leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio-Pharma says ARDS-003 has potential to earn $500M in revenue from royalties, upfront payments by 2026

The firm calculated the potential revenues based on a conservative market penetration of the coronavirus, ARDS and sepsis markets

Tetra Bio-Pharma - Tetra Bio-Pharma says ARDS-003 has potential to earn $500M in revenue from royalties, upfront payments by 2026
Initial drug indication for the Canadian company's investigational new drug ARDS-003 targets COVID-19 related survival benefits

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery, updated investors on Wednesday on the high potential of ARDS-003, its investigational new drug designed to dampen the so-called "cytokine storm" and prevent the development of Acute Respiratory Distress Syndrome (ARDS), the life-threatening condition seen in serious coronavirus (COVID-19) cases. 

“Based on a conservative market penetration and patient-based model, Tetra estimates potential revenues from royalties on net sales, milestone and upfront payments of over US$500 million by 2026,” said the Canadian biopharmaceutical company in a statement. 

The Ottawa-based company said the patient-based model assumes “low-to-moderate penetration of the COVID-19 market” along with a “small penetration of the sepsis market.” Sepsis is a life-threatening medical emergency where the body has an extreme response to an infection. Tetra Bio-Pharma’s revenue calculation considers a small penetration during ongoing clinical trials of ARDS-003 in sepsis-related indications to expand claims through supplemental marketing approval applications.

READ: Tetra Bio-Pharma inks research deal to study ARDS-003 in coronavirus animal model

The company said ARDS-003 is an optimized sterile nano-emulsion of a synthetic compound that meets pharma standards to be intravenously administered to potentially treat systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, cytokine release syndrome (CRS), acute respiratory distress syndrome (ARDS) and multi-organ disfunction syndrome (MODS).

Tetra Bio-Pharma is planning to submit an application for a Phase I clinical trial to demonstrate safety in healthy volunteers and define the pharmacokinetic profile of ARDS-003, prior to initiating studies in patients with COVID-19.

Tetra Bio-Pharma CEO Guy Chamberland said: "Tetra is dedicated to developing ARDS-003 as a new therapeutic for reducing the severity of the exaggerated inflammatory responses that lead to acute respiratory distress or sepsis. Our focus is both on patient survival and post-survival care.”

“Tetra's science and innovation in exaggerated inflammatory reactions is among the top in the world. Our recent preclinical studies show that this drug will also play a role in post-survival patient care. The potential revenues to Tetra are based on a conservative market penetration of the entire ARDS, sepsis, and COVID-19 markets.”

The Tetra Bio-Pharma boss added that he was “very confident that this drug will play a significant role in addressing the needs of these markets."

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Tetra Bio-Pharma

Price: 0.195 CAD

TSX:TBP
Market: TSX
Market Cap: $54.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma makes progress with inhaled THC-based drug in meeting with...

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive the group it held a Type B meeting with the FDA for an inhaled THC-based innovative drug for the treatment of chemotherapy-induced nausea and vomiting (CINV). Chamberland says new drug will be part its...

on 16/12/20

2 min read